Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
28 juin 2023 08h00 HE
|
Esperion Therapeutics, Inc.
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) -- Esperion...
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
24 juin 2023 14h30 HE
|
Esperion Therapeutics, Inc.
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction...
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
15 juin 2023 14h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented results from an analysis comparing the cardiovascular risk reduction benefits of bempedoic acid treatment...
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
08 juin 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association’s 83rd Scientific...
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
05 juin 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 05, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at ENDO 2023 taking place June 15-18, 2023, in Chicago, IL. On...
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
01 juin 2023 08h00 HE
|
Esperion Therapeutics, Inc.
– Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering – – Anticipated approvals in U.S. in the first half of 2024 – ANN ARBOR,...
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
25 mai 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time...
Esperion to Participate in Jefferies Healthcare Conference
24 mai 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12 mai 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 9, 2023, the Company granted 13 new employees 71,500 restricted stock units (RSUs) under...
Esperion Reports First Quarter 2023 Financial Results
09 mai 2023 07h00 HE
|
Esperion Therapeutics, Inc.
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position...